Fas Antigen Expression on Hepatocytes Predicts the Short- and Long-term Response to Interferon Therapy in Patients with Chronic Hepatitis C

References

• Erickson AL, Houghton M, Choo QL, Weiner AJ, Ralston R, Muchmore E, et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993;151:4189–99.
   PubMed Web of Science ®Google Scholar
• Shirai M, Akatsuka T, Pendleton CD, Houghten R, Wychowski C, Mihalik K, et al. Induction of cytotoxic T cells to a crossreactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol 1992;66:4098–106.
   PubMedGoogle Scholar
• Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995; 92:2755–9.
   PubMed Web of Science ®Google Scholar
• Weis M, Schlegel J, Kass GE, Holmstrom TH, Peters I, Eriksson J, et al. Cellular events in Fas/APO-1-mediated apoptosis in JURKAT T lymphocytes. Exp Cell Res 1995;219:699–708.
   PubMed Web of Science ®Google Scholar
• Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994;19:1354–9.
   PubMed Web of Science ®Google Scholar
• Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994;204:468–74.
   PubMed Web of Science ®Google Scholar
• Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepatol 1995;2:91–6.
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Cromie SL, Bowden DS, Finch CF, Dudley FJ. Chronic hepatitis C and interferon alfa therapy: predictors of long term response. Med J Aust 1996;164:150–2.
   Google Scholar
• Martinot PM, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22:1050–6.
   PubMedGoogle Scholar
• Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995;122:161–8.
   Google Scholar
• Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351–4.
   PubMed Web of Science ®Google Scholar
• Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, et al. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995;226:120–9.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Stauber R, Propst A, Fiedler R, Muller C, Gschwantler M, et al. Dose increase augments response rate to interferon-alpha in chronic hepatitis C. Dig Dis Sci 1996;41 Suppl 12:103–8.
   Google Scholar
• Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778–9.
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24:1034–40.
   PubMed Web of Science ®Google Scholar
• Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995;22:700–6.
   PubMed Web of Science ®Google Scholar
• Iino S. High dose interferon treatment in chronic hepatitis C. Gut 1993;34 Suppl 2:114–8.
   Google Scholar
• Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994;89:681–6.
   PubMedGoogle Scholar
• Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
   PubMed Web of Science ®Google Scholar
• Hinshaw VS, Olsen CW, Dybdahl SN, Evans D. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol 1994;68:3667–73.
   PubMed Web of Science ®Google Scholar
• Tropea F, Troiano L, Monti D, Lovato E, Malorni W, Rainaldi G, et al. Sendai virus and herpes virus type 1 induce apoptosis in human peripheral blood mononuclear cells. Exp Cell Res 1995; 218:63–70.
   PubMedGoogle Scholar
• Cohen JJ. Apoptosis. Immunol Today 1993;14:126–30.
   PubMedGoogle Scholar
• Boise LH, Gonzalez GM, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597–8.
   PubMed Web of Science ®Google Scholar
• Borzillo GV, Endo K, Tsujimoto Y. Bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multistep process in culture. Oncogene 1992;7: 869–76.
   Google Scholar
• Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995;80:279–84.
   PubMed Web of Science ®Google Scholar
• Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol 1993;74:2347–55.
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494–500.
   PubMed Web of Science ®Google Scholar
• Tarao K, Takamiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688–94.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174–81.
   PubMed Web of Science ®Google Scholar
• Okazaki M, Hino K, Fujii K, Kobayashi N, Okita K. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996;41:2453–8.
   Google Scholar